Onconetix, Inc. (NASDAQ:ONCO) Short Interest Up 161.3% in March
by Renee Jackson · The Cerbat GemOnconetix, Inc. (NASDAQ:ONCO – Get Free Report) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totaling 680,001 shares, an increase of 161.3% from the March 15th total of 260,259 shares. Currently, 104.8% of the shares of the company are sold short. Based on an average daily trading volume, of 5,931,820 shares, the short-interest ratio is currently 0.1 days.
Institutional Trading of Onconetix
A hedge fund recently bought a new stake in Onconetix stock. Pacific Capital Wealth Advisors Inc. acquired a new position in Onconetix, Inc. (NASDAQ:ONCO – Free Report) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 13,000 shares of the company’s stock, valued at approximately $40,000. Pacific Capital Wealth Advisors Inc. owned 0.84% of Onconetix at the end of the most recent reporting period. 23.89% of the stock is currently owned by institutional investors.
Onconetix Stock Down 26.6%
Shares of NASDAQ:ONCO traded down $0.29 during midday trading on Monday, reaching $0.80. The company’s stock had a trading volume of 7,162,618 shares, compared to its average volume of 4,954,542. The firm has a market capitalization of $528,000.00, a PE ratio of 0.00 and a beta of 3.63. Onconetix has a twelve month low of $0.75 and a twelve month high of $74.29. The stock has a fifty day moving average of $3.44 and a 200 day moving average of $9.25.
About Onconetix
Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.